PI
VRTX icon

PEAK6 Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

PEAK6 Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$233K Buy
+500
New +$240K ﹤0.01% 2706
2024
Q2 		– Sell
-1,700
Closed -$711K – 4404
2024
Q1 		$711K Sell
1,700
-1,800
-51% -$761K ﹤0.01% 2188
2023
Q4 		$1.42M Sell
3,500
-200
-5% -$73.9K 0.01% 1804
2023
Q3 		$1.29M Buy
3,700
+1,700
+85% +$595K 0.01% 1636
2023
Q2 		$704K Sell
2,000
-900
-31% -$303K ﹤0.01% 1947
2023
Q1 		$914K Sell
2,900
-7,100
-71% -$2.13M ﹤0.01% 1919
2022
Q4 		$2.89M Buy
10,000
+2,700
+37% +$823K 0.02% 1061
2022
Q3 		$2.11M Sell
7,300
-54,700
-88% -$15.7M 0.01% 1510
2022
Q2 		$17.6M Sell
62,000
-49,100
-44% -$13.1M 0.03% 522
2022
Q1 		$29M Sell
111,100
-44,600
-29% -$10.6M 0.06% 286
2021
Q4 		$34.2M Sell
155,700
-18,500
-11% -$3.6M 0.07% 256
2021
Q3 		$31.6M Buy
174,200
+77,100
+79% +$15.1M 0.07% 239
2021
Q2 		$19.6M Buy
97,100
+23,800
+32% +$4.98M 0.05% 376
2021
Q1 		$15.8M Sell
73,300
-122,600
-63% -$26.9M 0.04% 432
2020
Q4 		$46.3M Buy
195,900
+117,300
+149% +$26.9M 0.1% 181
2020
Q3 		$21.4M Sell
78,600
-11,200
-12% -$3.09M 0.05% 312
2020
Q2 		$26.1M Buy
89,800
+18,900
+27% +$5.12M 0.09% 198
2020
Q1 		$16.9M Sell
70,900
-24,800
-26% -$5.69M 0.1% 192
2019
Q4 		$21M Sell
95,700
-68,800
-42% -$13.9M 0.11% 174
2019
Q3 		$27.9M Buy
164,500
+55,700
+51% +$9.85M 0.17% 95
2019
Q2 		$20M Buy
108,800
+23,100
+27% +$4.04M 0.13% 157
2019
Q1 		$15.8M Buy
85,700
+48,700
+132% +$8.99M 0.09% 224
2018
Q4 		$6.13M Buy
37,000
+600
+2% +$104K 0.04% 532
2018
Q3 		$7.02M Buy
+36,400
New +$6.48M 0.03% 610

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PEAK6 Investments's VRTX Position: Q3 2024 in Review

PEAK6 Investments increased its Vertex Pharmaceuticals (VRTX) stake by 8,200% in Q3 2024, buying an estimated $39.4K and bringing the position to 83 shares worth $38.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3144.

PEAK6 Investments first reported a position in VRTX in Q1 2019 and has held it in 19 quarters since. The position peaked at $12.4M in Q4 2020. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • PEAK6 Investments held 83 shares of Vertex Pharmaceuticals worth $38.7K as of Q3 2024.
  • PEAK6 Investments bought 82 Vertex Pharmaceuticals shares in Q3 2024, an estimated $39.4K.
  • Vertex Pharmaceuticals made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #3144 holding.
  • PEAK6 Investments first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 19 quarters since.
  • PEAK6 Investments's Vertex Pharmaceuticals position peaked at $12.4M in Q4 2020.
  • 1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.